NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Lipocine Inc. LPCN
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.0M
▼ 82.3% vs FY2024
EPS · FY25
$-1.69
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-54.3%
Net margin · FY25
-487.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.0M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 487 cents on every revenue dollar this year.
Per share
USD -1.69
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-54.3%
Return on equity, FY2025
ROE
Operating margin-524.7%
Net margin-487.1%
Return on assets-48.7%
Each USD of equity lost 54 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+58.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+71.5%
Change, 10 years—
The share count grew 72% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 17.0M
total assets, end of FY2025
Total assetsUSD 17.0M
EquityUSD 14.5M
CashUSD 5.2M
Current ratio6.68×
Equity funds 85% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
·
Net income $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
EPS, diluted $
−1.69
·
−3.14
−2.15
−0.01
−0.38
−0.50
−0.55
−1.05
−1.04
−1.11
−1.60
−1.44
0.85
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−54.3
0.0
−58.4
−26.5
−2.1
−193.9
−165.5
−82.1
−93.3
−55.8
−53.3
−57.2
−42.2
117.5
−0.4
Shares out B
0.01
0.01
0.01
0.01
0.09
0.07
0.04
0.02
0.02
0.02
0.02
0.01
0.01
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed